Karyopharm Therapeutics (KPTI) PT Lowered to $7 at Piper Sandler
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall St on pace for higher open as oil pulls back ahead of Fed decision
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailGet Alerts KPTI Hot Sheet
Price: $0.43 -10.42%
Rating Summary:
11 Buy, 6 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 17 | New: 16
Rating Summary:
11 Buy, 6 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 17 | New: 16
Join SI Premium – FREE
Piper Sandler analyst Edward A. Tenthoff lowered the price target on Karyopharm Therapeutics (NASDAQ: KPTI) to $7.00 (from $16.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Principal Financial Group (PFG) PT Lowered to $112 at UBS
- Columbia Banking System (COLB) PT Raised to $33 at TD Cowen
- KPJ Healthcare Bhd (KPJ:MK) PT Lowered to MYR3.10 at JPMorgan
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
